Women's Health
Wegovy for Women Over 40
Quick Answer: Wegovy (semaglutide 2.4 mg) can be an effective weight loss treatment for women over 40, including those experiencing perimenopausal or menopausal weight changes. Clinical trial data shows average weight loss of approximately 15% of body weight over 68 weeks — results broadly consistent across age groups. Hormonal changes after 40 make weight loss harder through multiple mechanisms, and Wegovy's appetite-regulating action addresses several of these directly.15%average weight loss at 68 weeks (STEP 1 trial)
40s–60smost common age range for Wegovy patients
2×increased abdominal fat risk post-menopause
The Biology
Why Weight Loss Changes After 40 for Women
Many women over 40 describe doing the same things they have always done but finding that weight accumulates more easily and responds less readily to diet and exercise. This is not imagined. The biological environment changes substantially in the decade between 40 and 50, driven primarily by hormonal transitions but compounded by changes in metabolism, muscle mass and sleep.
Perimenopause typically begins between the ages of 40 and 45. During this phase, oestrogen and progesterone levels become erratic and progressively decline. This hormonal instability affects fat distribution, metabolic rate, sleep quality, mood and hunger regulation. As oestrogen declines, fat redistributes from hips and thighs to the abdomen — the more metabolically dangerous visceral fat distribution.
How Each Hormone Affects Weight — and How Wegovy Helps
Oestrogen
Fat distribution & insulin sensitivity
Declining levels drive visceral fat accumulation and reduce insulin sensitivity, making calories more likely to be stored as fat.
→ Wegovy's appetite suppression reduces overall calorie intake, counteracting increased energy storage tendency.
Progesterone
Sleep, mood & cravings
Declining progesterone disrupts sleep quality and increases cravings, particularly for high-carbohydrate comfort foods.
→ Reduced appetite on Wegovy blunts progesterone-driven cravings, making dietary adherence significantly easier.
Insulin
Blood glucose & fat storage
Increasing insulin resistance with age means more insulin is required to manage blood glucose, promoting fat storage.
→ Semaglutide improves insulin sensitivity and reduces post-meal glucose excursions directly.
Leptin & Ghrelin
Hunger & fullness signals
Shifts after 40 can blunt leptin (fullness) signalling and amplify ghrelin (hunger), creating a physiological drive toward overconsumption.
→ Wegovy's GLP-1 agonism reinforces satiety signals and reduces the hunger drive directly.
Expected Results
Weight Loss Timeline for Women Over 40
Women over 40 can expect broadly similar weight loss outcomes to those reported in the overall STEP 1 trial population. Patients in perimenopause who are experiencing the most significant hormonal flux may find their weight loss trajectory is slightly less linear, with periods of plateau corresponding to hormonal shifts. This is normal and does not indicate treatment failure.
Safety Considerations for Women Over 40
| Timepoint | Expected Weight Loss | Key Changes |
|---|---|---|
| Month 1–2 | 1–4 kg (1–4%) | Appetite reduction begins; energy levels may dip initially |
| Month 3 | 5–7% | Noticeable weight loss; clothing size may begin to change |
| Month 6 | ~10% | Significant visceral fat reduction; metabolic markers improving |
| Month 12 | ~14–15% | Full treatment effect; sustained weight loss with lifestyle support |
| Consideration | Detail | Action Required |
|---|---|---|
| Bone density | Rapid weight loss can reduce bone mineral density; risk higher post-menopause | Weight-bearing exercise and adequate calcium/vitamin D throughout treatment |
| HRT interaction | No known pharmacokinetic interaction between semaglutide and HRT | Inform prescribing clinician of all medications including HRT |
| Gallbladder risk | Weight loss increases gallstone risk in women | Be aware of upper right abdominal pain; report to clinician promptly |
| Fertility | Weight loss can restore ovulation in women with anovulatory cycles | Use contraception if pregnancy is not desired; Wegovy not recommended in pregnancy |
FAQs
Frequently Asked Questions: Wegovy for Women Over 40
Yes. Clinical trial data from the STEP programme — in which the majority of participants were women with a mean age of 46 — demonstrates average weight loss of approximately 15% of body weight over 68 weeks on semaglutide 2.4 mg. Wegovy's mechanism of action addresses several of the specific physiological challenges women over 40 face directly.
Weight loss becomes harder after 40 for women due to a convergence of hormonal and metabolic changes: declining oestrogen drives fat redistribution to the abdomen and reduces insulin sensitivity; declining muscle mass lowers resting metabolic rate; disrupted sleep from perimenopause elevates cortisol and hunger hormones. This is not a failure of willpower — it is a biological reality that pharmacological support can meaningfully address.
There is no known pharmacokinetic interaction between semaglutide and HRT. Women currently taking HRT who meet Wegovy's eligibility criteria can be prescribed both, subject to clinical assessment. Inform your prescribing pharmacist of all medications, including HRT type and dose, before starting Wegovy.
Weight loss on Wegovy includes a meaningful reduction in visceral (abdominal) fat. STEP 1 trial participants experienced average waist circumference reductions of 10–14 cm. This is particularly significant for women over 40, for whom visceral fat accumulation is the primary driver of increased cardiovascular and metabolic risk.
Yes. Perimenopause is not a contraindication to Wegovy. Women in the perimenopausal transition who meet the BMI and clinical eligibility criteria may be prescribed Wegovy following an appropriate assessment. The hormonal changes of perimenopause may affect the pace of weight loss but do not prevent Wegovy from working.
Weight loss — particularly rapid weight loss — can reduce bone mineral density, which is a relevant consideration for post-menopausal women at increased osteoporosis risk. Maintaining adequate calcium and vitamin D intake and incorporating weight-bearing and resistance exercise throughout Wegovy treatment are strongly recommended.
Ready to Start Wegovy Treatment?
GPhC-registered pharmacy (No. 9012585) · UK-licensed prescribers · Free online assessment
Check Your Eligibility →
Wilding JPH et al. STEP 1. N Engl J Med. 2021. Davis SR et al. Menopause. Nat Rev Dis Primers. 2015. Tchernof A, Despres JP. Physiol Rev. 2013. NICE TA875. 2023. Happy Pharmacy (GPhC No. 9012585). Educational purposes only — not medical advice.